LL 4218Alternative Names: Desoside-P; LL-4218
Latest Information Update: 05 Apr 2011
At a glance
- Originator Lupin
- Class Antipsoriatics
- Mechanism of Action Cell modulators
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Plaque psoriasis
Most Recent Events
- 05 Apr 2011 No development reported - Phase-II for Plaque psoriasis in India (PO)